The drug also delivered a disease control rate (DCR) of 83.3% in high-dose cohorts and a mean progression-free survival of 6.3 months in SCLC patients
Despite the strong results, investigators cautioned that the study has limitations, including its open-label Phase II design, lack of randomization, and reliance on a historical external control arm
AstraZeneca highlighted the move as a major step toward earlier intervention in curable disease
Access to genomic testing, not therapy cost, is the biggest challenge
The acquisition positions Roche more aggressively in digital pathology and precision diagnostics capabilities
The Committee backed the combination based on results from the CAPItello-281 Phase III trial, marking a key milestone in the regulatory pathway for AstraZeneca’s targeted therapy strategy in prostate cancer
But acquisition charges drag earnings into loss
While Drugs for Neglected Diseases initiative (DNDi) drives the R&D for neglected diseases, we collaborate with pharmaceutical companies at multiple stages, including sourcing promising molecules
Patients receiving ELREXFIO largely remained free from disease progression during the interim analysis
The investigational therapy, MDX2003, is designed to go after cancer cells with a multi-pronged immune attack
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
